Actual adherence to dimethyl fumarate in patients with relapsing-remitting multiple sclerosis
INTRODUCTION: Multiple sclerosis is a chronic neurological disease with numerous disease-modifying treatments available, including dimethyl fumarate (DMF), a first-line therapy for relapsing-remitting multiple sclerosis. Although rates of discontinuation of DMF are generally low in clinical trials, non-adherence to treatment is associated with poorer clinical outcomes. Assessing real-world adherence and predictive factors is critical to be able to improve clinical outcomes for patients. This study evaluated adherence to DMF over 24 months in a cohort of patients treated in a Portuguese healthcare centre.
PATIENTS AND METHODS: A prospective, non-interventional, single-centre study with 24 months' follow-up was conducted. The study included adult patients with relapsing-remitting multiple sclerosis treated with DMF in routine clinical practice. Adherence to DMF was calculated and patients were considered to have adhered if the value was above 80%. Clinical and socio-demographic variables were compared between groups.
RESULTS: Of the 80 patients included, 74% were women, with a mean age of 39 years and a mean age of 32 years at diagnosis. Twenty-six patients had not received any previous treatment. Adherence varied between 93, 82 and 87.5% at 6, 12 and 24 months, respectively. No differences were found between patients who had not received any prior treatment and those who had been treated.
CONCLUSION: This real-world analysis showed significant adherence to DMF treatment by Portuguese patients over a period of two years. However, these results must be interpreted in the light of the substantial changes in outpatient consultations and the various periodic restrictions due to the COVID-19 pandemic, which had an important effect on patient follow-up and data collection.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:76 |
|---|---|
| Enthalten in: |
Revista de neurologia - 76(2023), s01 vom: 31. Jan., Seite S1-S6 |
| Sprache: |
Spanisch |
|---|
| Weiterer Titel: |
Adhesión real al dimetilfumarato en pacientes con esclerosis múltiple remitente-recurrente |
|---|
| Beteiligte Personen: |
de Sá, J [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Dimethyl Fumarate |
|---|
| Anmerkungen: |
Date Completed 24.01.2023 Date Revised 21.11.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.33588/rn.76s01.2022296 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM351939776 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM351939776 | ||
| 003 | DE-627 | ||
| 005 | 20231226052607.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||spa c | ||
| 024 | 7 | |a 10.33588/rn.76s01.2022296 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1173.xml |
| 035 | |a (DE-627)NLM351939776 | ||
| 035 | |a (NLM)36683265 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a spa | ||
| 100 | 1 | |a de Sá, J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Actual adherence to dimethyl fumarate in patients with relapsing-remitting multiple sclerosis |
| 246 | 3 | 3 | |a Adhesión real al dimetilfumarato en pacientes con esclerosis múltiple remitente-recurrente |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.01.2023 | ||
| 500 | |a Date Revised 21.11.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: Multiple sclerosis is a chronic neurological disease with numerous disease-modifying treatments available, including dimethyl fumarate (DMF), a first-line therapy for relapsing-remitting multiple sclerosis. Although rates of discontinuation of DMF are generally low in clinical trials, non-adherence to treatment is associated with poorer clinical outcomes. Assessing real-world adherence and predictive factors is critical to be able to improve clinical outcomes for patients. This study evaluated adherence to DMF over 24 months in a cohort of patients treated in a Portuguese healthcare centre | ||
| 520 | |a PATIENTS AND METHODS: A prospective, non-interventional, single-centre study with 24 months' follow-up was conducted. The study included adult patients with relapsing-remitting multiple sclerosis treated with DMF in routine clinical practice. Adherence to DMF was calculated and patients were considered to have adhered if the value was above 80%. Clinical and socio-demographic variables were compared between groups | ||
| 520 | |a RESULTS: Of the 80 patients included, 74% were women, with a mean age of 39 years and a mean age of 32 years at diagnosis. Twenty-six patients had not received any previous treatment. Adherence varied between 93, 82 and 87.5% at 6, 12 and 24 months, respectively. No differences were found between patients who had not received any prior treatment and those who had been treated | ||
| 520 | |a CONCLUSION: This real-world analysis showed significant adherence to DMF treatment by Portuguese patients over a period of two years. However, these results must be interpreted in the light of the substantial changes in outpatient consultations and the various periodic restrictions due to the COVID-19 pandemic, which had an important effect on patient follow-up and data collection | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Dimethyl Fumarate |2 NLM | |
| 650 | 7 | |a FO2303MNI2 |2 NLM | |
| 650 | 7 | |a Immunosuppressive Agents |2 NLM | |
| 700 | 1 | |a Ferreira, J |e verfasserin |4 aut | |
| 700 | 1 | |a Macedo, A M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Revista de neurologia |d 1994 |g 76(2023), s01 vom: 31. Jan., Seite S1-S6 |w (DE-627)NLM074738666 |x 1576-6578 |7 nnns |
| 773 | 1 | 8 | |g volume:76 |g year:2023 |g number:s01 |g day:31 |g month:01 |g pages:S1-S6 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.33588/rn.76s01.2022296 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 76 |j 2023 |e s01 |b 31 |c 01 |h S1-S6 | ||